{'fraction_non_alphanumeric': 0.029411764705882353, 'fraction_numerical': 0.0055147058823529415, 'mean_word_length': 5.337209302325581, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
KL‐6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non‐small cell lung cancer

Background and objective:  Both Krebs von den Lungen‐6 (KL‐6) and carcinoembryonic antigen (CEA) are known to be tumour markers in non‐small cell lung cancer (NSCLC). The aim of the present study was to assess whether or not intrabronchial epithelial lining fluid (ELF) levels of these markers predicted tumour response better than serum levels in patients with advanced NSCLC treated with gefitinib.